Medpace Holdings, Inc. insider trading
Every open-market purchase and sale by Medpace Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Medpace Holdings, Inc.’s insiders pay?
From August 22, 2017 to October 28, 2026, 15 insiders reported 11 open-market purchases and 118 sales not made under a pre-set plan in Medpace Holdings, Inc. Twelve months after each purchase was reported, the shares were +51.0% against the S&P 500 on average (median +49.1%), over 11 purchases with a full year of prices; 100% beat the index. After sales, the shares moved −4.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 23, 2022 into $16,790 by November 2, 2026, +11.7% a year. It held shares 25% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $11,827 (+3.7% a year), and held throughout $19,101 (+14.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Troendle August J. | President & CEO | 10 | +51.9% (10) | 100% | 46 | −24.6% (25) | October 1, 2026 |
| Burwig Susan E | Exec. VP, Operations | 0 | — | — | 14 | −8.9% (10) | October 28, 2026 |
| Geiger Jesse J | President | 0 | — | — | 13 | +2.1% (12) | March 19, 2026 |
| Ewald Stephen P | General Counsel & Corp. Secy. | 0 | — | — | 11 | +1.6% (10) | June 1, 2026 |
| Keating Ashley M. | Director | 0 | — | — | 7 | −16.7% (7) | March 18, 2024 |
| Brady Kevin M. | CFO & Treasurer | 0 | — | — | 6 | +15.0% (4) | August 24, 2026 |
| Kraft Robert O. | Director | 0 | — | — | 5 | +15.7% (3) | August 28, 2026 |
| Davenport Fred B Jr | Director | 1 | +42.1% (1) | 100% | 3 | +5.5% (1) | August 21, 2026 |
| Mccarthy Cornelius P. III | Director | 0 | — | — | 3 | +12.4% (1) | August 13, 2026 |
| Carley Brian T | Director | 0 | — | — | 2 | +21.6% (1) | August 21, 2026 |
| Cinven Capital Management (v) Limited Partnership Inc | 10% owner | 0 | — | — | 2 | +47.8% (2) | August 27, 2018 |
| King Tom C | Director | 0 | — | — | 2 | +3.7% (2) | November 5, 2021 |
| Medpace Gp Ltd | 10% owner | 0 | — | — | 2 | +27.8% (2) | August 10, 2018 |
| Cinven Capital Management (v) General Partner Ltd | 10% owner | 0 | — | — | 1 | +64.1% (1) | December 7, 2017 |
| Medpace Limited Partnership | 10% owner | 0 | — | — | 1 | +32.5% (1) | May 8, 2018 |
When several insiders traded Medpace Holdings, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Medpace Holdings, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +28.6% against the index. After 9 selling crowds, +4.2%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| July 31, 2026 | 3 selling | +14.2% | not yet | not yet |
| July 31, 2025 | 5 selling | +27.8% | +26.2% | +13.0% |
| December 29, 2023 | 3 selling | +18.6% | +15.7% | −16.5% |
| August 31, 2023 | 3 selling | −1.5% | +34.2% | +5.2% |
| November 30, 2022 | 4 selling | −4.4% | −4.8% | +16.8% |
| July 29, 2022 | 2 buying | +34.9% | +28.6% | +38.2% |
| October 29, 2021 | 4 selling | −20.0% | −30.1% | +12.6% |
| August 31, 2021 | 3 selling | +12.5% | −14.3% | −7.8% |
| March 31, 2021 | 3 selling | −0.7% | +4.1% | −17.6% |
| August 31, 2020 | 3 selling | −5.2% | +16.4% | +9.3% |
| August 31, 2018 | 3 selling | +8.2% | −9.3% | +32.8% |